69.30 0.00 (0.00%)
After hours: 5:06PM EST
|Bid||69.31 x 800|
|Ask||69.32 x 800|
|Day's range||68.52 - 69.64|
|52-week range||56.58 - 72.81|
|Beta (3Y monthly)||0.78|
|PE ratio (TTM)||20.92|
|Earnings date||18 Feb 2020 - 24 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.27|
We'd be surprised if Henry Schein, Inc. (NASDAQ:HSIC) shareholders haven't noticed that an insider, Paul Brons...
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In 1989 Stanley Bergman was appointed CEO of Henry Schein, Inc. (NASDAQ:HSIC). First, this article will compare CEO...
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Henry Schein (HSIC) delivered earnings and revenue surprises of 1.20% and -1.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - Henry Schein reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that fell short of forecasts.
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.